Bayer Files New Drug Application for Elinzanetant With FDA
By Mauro Orru
Bayer said it has submitted a new drug application with the Food and Drug Administration for elinzanetant, an investigational compound for the treatment of moderate to severe vasomotor symptoms linked with menopause.
The German pharmaceutical and agricultural conglomerate said the decision was based on positive results from the several studies and that it would also submit applications for marketing authorizations to other health authorities.
"The FDA submission for elinzanetant marks a significant milestone in our efforts to offer a new non-hormonal option for women," said Christine Roth, executive vice president for global product strategy and commercialization.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
August 01, 2024 03:05 ET (07:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States